Trial Profile
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Thromboembolism
- Focus Adverse reactions
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 12 Jul 2018 Status changed from active, no longer recruiting to completed.
- 14 Jun 2018 Planned End Date changed from 1 Aug 2017 to 1 Jun 2018.